CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma

CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma

Abstract Relapsed/refractory (R/R) primary and secondary central nervous system lymphomas (PCNSL, SCNSL) are associated with short survival and represent an unmet need, requiring novel effective strategies. We retrospectively compared the safety and efficacy of CD19/22 CAR-T-cell therapy following A...

Full description

Bibliographic Details
Main Authors: Xiaoxi Zhou, Qiuxia Yu, Zigang Dai, Jue Wang, Chunrui Li, Liang Huang, Yicheng Zhang, Yang Cao
Format: Article
Language:English
Published: BMC 2024-10-01
Series:Experimental Hematology & Oncology
Subjects:
CNS lymphoma
CAR-T-cell therapy
ASCT
Adverse events
Efficacy
Online Access:https://doi.org/10.1186/s40164-024-00538-y

Internet

https://doi.org/10.1186/s40164-024-00538-y

Similar Items